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MTI-101 treatment inducing 
activation of Stim1 and TRPC1 
expression is a determinant of 
response in multiple myeloma
Michael F. Emmons1,2, Nagaraju Anreddy3, Javier Cuevas4, Kayla Steinberger3, Shengyu 
Yang1, Mark McLaughlin3, Ariosto Silva5 & Lori A. Hazlehurst3
The emergence of drug resistance continues to be a major hurdle towards improving patient outcomes 
for the treatment of Multiple Myeloma. MTI-101 is a first-in-class peptidomimetic that binds a CD44/
ITGA4 containing complex and triggers necrotic cell death in multiple myeloma cell lines. In this report, 
we show that acquisition of resistance to MTI-101 correlates with changes in expression of genes 
predicted to attenuate Ca2+ flux. Consistent with the acquired resistant genotype, MTI-101 treatment 
induces a rapid and robust increase in intracellular Ca2+ levels in the parental cells; a finding that was 
attenuated in the acquired drug resistant cell line. Mechanistically, we show that pharmacological 
inhibition of store operated channels or reduction in the expression of a component of the store 
operated Ca2+ channel, TRPC1 blocks MTI-101 induced cell death. Importantly, MTI-101 is more potent 
in specimens obtained from relapsed myeloma patients, suggesting that relapse may occur at a cost 
for increased sensitivity to Ca2+ overload mediated cell death. Finally, we demonstrate that MTI-101 
is synergistic when combined with bortezomib, using both myeloma cell lines and primary myeloma 
patient specimens. Together, these data continue to support the development of this novel class of 
compounds for the treatment of relapsed myeloma.
Although there has been considerable progress in the treatment and survival rates of patients with multiple 
myeloma (MM), this malignancy remains an essentially incurable disease in dire need of new treatment strat-
egies1, 2. We propose that targeting Ca2+ homeostasis is a tractable approach for treating MM that is resistant 
to standard-of-care agents. In support of this notion, recent studies have shown that cancer cells rewire their 
Ca2+ circuitry, including increased expression of components of store-operated channels (SOC) such as Ca2+ 
Release-activated Ca2+ Modulator 1 (Orai1), stromal interaction molecule 1 (STIM1), and the transient recep-
tor potential channel 1 (TRPC1)3, 4. Moreover, SOCs appear to contribute to oncogene-mediated proliferation, 
migration and metastasis of cancer cells5–7. Accordingly, we reasoned that remodeling Ca2+ homeostasis of cancer 
cells provides an attractive therapeutic opportunity, as Ca2+ overload can trigger cell death8.
Intracellular Ca2+ levels are controlled by signals emanating from the plasma membrane, including 
G-protein-coupled receptors (GPCR), receptor tyrosine kinases (RTK), and cell adhesion molecules, includ-
ing CD449. Ca2+ homeostasis relies on the activation of specific phospholipases, including phospholipase-C β 
(PLCβ) by Gq/11 GPCRs or Phospholipase-C γ (PLCγ) by RTKs. These phospholipases cleave phosphatidylinosi-
tol 4,5-bisphosphate (PIP2) into the secondary messenger’s inositol triphosphate (IP3) and diacylglycerol (DAG). 
IP3 binds to the inositol triphosphate type 3 receptor (IP3R) on the endoplasmic reticulum (ER) membrane, 
which causes release of ER Ca2+ stores into the cytosol. ER Ca2+ depletion is then sensed by the scaffold protein 
STIM1, which changes its conformation and causes aggregation in the ER just below the cell membrane. Upon 
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aggregation, STIM1 interacts with Orai1 and TRPC1, an essential components of SOC, and this interaction then 
promotes Ca2+ influx into cytosol10, 11.
A large body of data suggests that alterations in Ca2+ homeostasis can provoke necrosis. Under normal phys-
iological conditions, extracellular Ca2+ is 5 mM whereas intracellular free Ca2+ ranges from 50 nM in the cytosol 
to ~500 µM in the ER. Specifically, prolonged elevation of free cytoplasmic Ca2+ (>1 µM) triggers mitochondria 
Ca2+ overload12, the opening of the mitochondrial permeability transition pore and the depletion of ATP, which 
leads to necrosis13. Furthermore, increased levels of cytoplasmic Ca2+ triggers the activation of Ca2+-dependent 
calpain proteases that permeabilize lysosomal membranes, thereby releasing lysosomal enzymes into the cyto-
plasm that also contribute to necrotic cell death14.
We recently showed that a D-amino acid linear peptide coined HYD1 and a more potent second-generation 
cyclized analog coined MTI-101 binds to a CD44/ITGA4-containing complex and provokes necrotic cell death15–17. 
The cell death pathway elicited by this novel class of molecules includes increased levels of reactive oxygen species 
(ROS), depolarization of the mitochondrial membrane potential, and depletion of ATP, all hallmarks of necrosis. 
Historically, necrosis was thought an uncontrolled form of cell death triggered by bioenergetic events that lead 
to a loss in osmolality, organelle and cell swelling and ultimately, cell lysis18. However, more recent studies have 
shown that necrosis can be triggered by “necroptotic” signaling pathways, including the Ripk1/Ripk3 circuit 
directed by tumor necrosis factor-alpha (TNFα)19–21.
Our recent studies demonstrated that MTI-101-induced cell death was only partially dependent on the 
TNFα-Ripk1/Ripk3 necroptotic pathway16. To gain insights into additional determinants of MTI-101-induced 
necrosis, we performed gene expression profiling on an acquired drug resistant cell line and found that genes 
predicted to attenuate store operated mediated Ca2+ flux were attenuated. Based on these data we hypothesized 
that Ca+ flux was a determinant of MTI-101 induced cell death in myeloma cell lines and primary patient spec-
imens. To address our hypothesis we used both shRNA strategies and pharmacological approaches to attenuate 
store operated Ca2+ flux and showed that this pathway was indeed a determinant of MTI-101 induced cell death.
Results
Treatment with MTI-101 or HYD1 Increases Intracellular Ca2+ Levels in MM Cells. To deter-
mine the mechanism by which HYD1 and its cyclic analogue MTI-101 induces cell death in NCI-H929 cells, we 
developed the HYD1-resistant isogenic cell line H929–6015, 16. As shown in Fig. 1A the IC50 value for H929 is 
1.2 +/− 1.15 uM while for, H929-60 cells the IC50 value was 9.3 +/− 1.08 uM towards MTI-101 induced growth 
arrest as measured by MTT assays (n = 3 independent experiments p < 0.05, t-test). Gene expression profiling 
of the parental and drug resistant variant was used to determine pathways that were altered as cells gained resist-
ance to MTI-101. Specifically, the expression of PLC-β, the IP3 isoform 3 receptor, TRPC1, and TRPM7 were all 
reduced in H929-60 cells (Table 1). Moreover ATP2A3 the SERCA channel was also downregulated in the drug 
resistant line (Table 1). Interestingly, recent studies indicate that TRPC1 and Orai1 expression regulate STIM1-
dependent Ca2+ entry22, 23. Moreover, TRPM7 is a substrate of MLKL (mixed-lineage kinase domain-like protein), 
which is phosphorylated by Ripk3 following treatment with TNFα, linking Ca2+ entry with the necroptotic cell 
death pathway24. As shown in Fig. 1B a subset of the genes identified by microarray analysis were validated by 
real-time RT-PCR (n = 3 independent experiments performed in triplicates p < 0.05, Student’s t-test) and western 
blot analysis, respectively (n = 3 independent experiments). Interestingly, TRPM6 and TRPM8 were increased 
in the resistant cell line and may contribute to maintaining Ca2+ homeostasis in the resistant cell line despite 
reduced expression of the store Ca2+ operated channel pathway.
To test if HYD1 or MTI-101 treatment affected intracellular Ca2+ levels, NCI-H929 and H929-60 cells were 
loaded with fura-2 dye, and time-lapse images were taken every ten seconds for either 60 min (HYD1) or for 
30 min (MTI-101) after treatment. Treatment with both HYD1 (75 µM) and MTI-101 (3 µM) triggered increases 
in intracellular Ca2+ levels in NCI-H929 and H929-60 cells. Furthermore, the levels of intracellular Ca2+ pools 
that were induced by MTI-101 were reduced in H929-60 vs. NCI-H929 cells (Fig. 1D), suggesting that HYD1- 
and MTI-101-induced MM death was due to Ca2+ overload. NCI-H929 cells were thus examined to assess if there 
were differences in total Ca2+ levels or differences in temporal Ca2+ levels after HYD1 or MTI-101 treatment. 
MTI-101 is more efficient in eliciting a Ca2+ response in MM cells than HYD1, consistent with the increased 
potency of MTI-101 vs. its linear counterpart on inducing cell death16. Collectively, these findings suggest that 
acquisition of resistance to this class of compounds is associated with changes in genes predicted to rewire Ca2+ 
homeostasis.
MTI-101-induced Increases in Intracellular Ca2+ are Caused by Release of Ca2+ From ER Stores 
and Ca2+ Entry via Store-operated Channels. Increase in intracellular Ca2+ occur either by influx 
through the plasma membrane channels or exchangers (i.e., voltage-gated channels, SOC, Na+-Ca2+ exchanger) 
or via release from internal stores such as the ER25–27. One means of Ca2+ release from ER stores is through the 
opening of the IP3R caused by PLC activation25. To test if activation of PLC was involved in MTI-101-induced 
intracellular Ca2+ increases, NCI-H929 or U266 cells were pre-treated with 2 µM or 1 µM of the PLC inhibi-
tor U7312228, respectively, and were then treated with MTI-101. This assay was performed in the presence and 
absence of extracellular Ca2+ to determine the effects of MTI-101 on Ca2+ influx to cells. After treatment with 
MTI-101, the effects on Ca2+ levels were measured using Fura-2. U73122 treatment decreased MTI-101-induced 
Ca2+ levels in both NCI-H929 (Fig. 2A) and U266 cells (data not shown); a finding that was further attenuated 
upon removal of extracellular Ca2+ indicating that increased levels of Ca2+ induced by MTI-101 occur via both 
release of ER stores and Ca2+ entry via store-operated channels. Although, we could not detect a decrease in 
peak levels of Ca2+ in the absence of the PLC inhibitor (Fig. 2B,C), removing extracellular Ca+2 reduced the 
MTI-101-induced sustained increases in Ca2+ levels (as measured by the area under the curve) in both H929 
and U266 cells (Fig. 2D,E). Together these data indicate that Ca2+ release from the ER, via activation of the IP3R, 
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contributes to the peak levels and Ca2+ entry through plasma membrane channels contribute to the sustained 
high levels of Ca2+ observed following treatment with MTI-101.
These findings suggest that blocking Ca2+ release from ER stores and/or Ca2+ entry would inhibit MTI-
101-induced cell death. Thus, we tested whether 2-APB, which blocks Ca2+ release through the IP3R as well as 
SOC-mediated Ca2+ entry29, affected MTI-101-induced myeloma cell death. Notably, both NCI-H929 and U266 
cells pretreated with 2-APB are resistant to MTI-101-induced cell death (Fig. 3A,B). To determine whether Ca2+ 
entry into mitochondria contributes to death we blocked the mitochondria uniporter with RU360. As shown in 
Fig. 3A,B pretreatment with RU360 blocks MTI-101 induced cell death (p < 0.05, students T-test). These data 
Figure 1. Selection for HYD1 resistance in NCI-H929 MM cells correlates with changes in Ca2+ signaling 
pathways. (A) Effect of MTI-101 on parentral (NCI-H929) and acquired drug resistant H929-60 cells. The 
H929-60 cells were developed by continuous exposure to the first generation linear peptide referred to as 
HYD-1. The H929-60 cell line is cross resistant to MTI-101 induced growth arrest. IC50 values of MTI-101 
were determined using the MTT cell viability assay. Each value in the curve is the average of 3 independent 
experiments ± standard deviation. The resistant cell line was 7.8 fold resistant (n = 3 independent experiments 
p < 0.05 t-test). (B,C) Select genes were further validated by real time RT-PCR (n = 3 independent experiments 
p < 0.05, Student’s t-test, multiple testing corrected by Bonferroni-Dunn method) and western blot analysis 
(n = 3 independent experiments, shown is a representative blot). (D) Effect of MTI-101 on intracellular Ca2+ 
levels in NCI-H929 and H929-60 cells. H929 and H929-60 MM cells were adhered to cell-tak coated plates 
and were incubated with Fura-2 dye for 30 min. Time-lapse images were taken every 10 seconds for either 
60 min after treatment with 75 µM HYD1 or 30 min after treatment with 3 µM MTI-101. Drug was delivered 
using a constant flow rate of continuous exposure of the drug. A one-way ANOVA test was used to determine 
significance (#p > 0.05; *p < 0.05; n = 30 or greater).
Gene 
Symbol
Average Signal +/− SD 
(n = 3) H929
Average Signal +/− SD 





ITPR3 891 +/− 3.8 474 +/− 33 0.53 0.0027
PLCB1 525.5 +/− 126 325.6 +/− 57.4 0.66 0.045
TRPC1 241.7 +/− 45.8 138.5 +/− 20.24 0.54 0.024
TRPM7 328.8 +/− 31 208.4 +/− 13.4 0.63 0.013
ATP2A3 1215 +/− 139 557 +/− 75 0.46 0.008
TRPM6 20.4 +/− 5.4 (A) 146 +/− 15.9 7.2 0.008
TRPM8 65.6 +/− 31 228.4 +/− 42 3.5 0.018
Table 1. Microarray gene expression profiling of NCI-H929 and H929-60 cells. The mean expression values of 
the three independent experiments were compared between NCI-H929 and H929-60 cell lines. Fold change was 
calculated by ratio between NCI-H929 H929-60 cell lines.
www.nature.com/scientificreports/
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suggest that MTI-101-induced cell death is, at least in part, due to Ca2+ overload of mitochondria. As shown in 
Fig. 3C,D, cells pre-treated with 2-APB and then treated with MTI-101 inhibits MTI-101-mediated increases 
in intracellular Ca2+ (Fig. 3C,D). Thus, blocking increases in intracellular Ca2+ is sufficient to inhibit MTI-101 
induced cell death.
To test whether MTI-101 induces activation of STIM1 as determined by the formation of punctae and traffick-
ing to ER/PM junctions, we used TIRF microscopy, which images 100 nm proximity of the surface of the slide. As 
shown in Fig. 4A,B, U266 cells which overexpress STIM1 m-cherry have significantly increased levels of Stim1 as 
determined by total fluorescence intensity near the plasma membrane (p < 0.05, Two-way ANOVA). To test the 
specific role of TRPC1, a component of the store-operated channels we used shRNA to reduce the expression of 
TRPC1. As shown in Fig. 4C,D, reducing the expression of TRPC1 significantly inhibits MTI-101 induced cell 
death (p < 0.05, student’s t-test).
MTI-101/Bortezomib Combination demonstrates Increased Anti-Myeloma Activity in vitro and 
In Vivo. Several reports indicated that blocking L-type Ca2+ channels or blocking Ca2+ uptake by inhibiting 
the mitochondria uniporter blocks cell death induced by bortezomib. In contrast, 2-APB was not shown to block 
bortezomib-induced cell death. It is attractive to speculate that increased Ca2+ via L-type, and store-operated 
channels converge to cause synergistic cell death via Ca2+ overload of the mitochondria in myeloma cells30, 31. 
Thus we next sought to determine the activity of MTI-101 in combination with the standard of care agent borte-
zomib in 5TGM1 cells (Fig. 5A). For 5TGM1 cells we utilized a bone marrow stroma co-culture model and 
time lapse imaging of individual cells to determine viability as function of time. Combination index was calcu-
lated at select time points using the Calcusyn software32, 33. As shown in Fig. 5A, in 5TGM1 cells when MTI1-
101 is combined with bortezomib synergy is observed, as defined by a combination index of less than 1 cells as 
early as 30 hours and was maintained to the endpoint of 72 hours. To test whether MTI-101 in combination with 
Bortezomib has anti-tumor activity in vivo C57BL/KaLwRijHsd mice (6- to 8-week old) were injected i.v. with 
syngeneic 5TGM1 MM cells and were then treated with MTI-101 (10 mg/kg) and/or bortezomib (0.5 mg/kg). As 
predicted, mice treated with MTI-101 or bortezomib had improved survival versus vehicle treated mice (Fig. 5B). 
Notably, the MTI-101/bortezomib combination had superior anti-myeloma activity versus single-agent treat-
ment. Specifically, mean survival times for vehicle control, bortezomib only, MTI-101 only, and MTI-101/borte-
zomib combination therapy were 36, 42, 45.5, and 72.5 days, respectively (p < 0.05, Log-Rank Test) (Fig. 5B). To 
Figure 2. MTI-101 triggers release of ER Ca2+stores and influx of Ca2+ entry by plasma membrane store 
operated channels (SOC). (A) MTI-101 mediated intracellular Ca2+ levels were measured by using Fura-2 dye. 
NCI-H929 cells were adhered to cell-tak coated plates and then incubated with Fura-2 dye +/− 2 uM U73122 
for 30 min in PSS containing Ca2+ and PSS without Ca2+. Time-lapse images were taken every 10 seconds for 
30 min after treatment with 3 µM MTI-101. A representative H929 cell closest to the median Ca2+ response of 
the whole population is shown. The peaks were then measured and subtracted from the baseline Ca2+ levels. A 
representative experiment for (B) NCI-H929 and (C) U266 is shown. (D and E) The total level of Ca2+ induced 
by MTI-101 was determined by measuring the area under the curve for each individual cell. A one-way ANOVA 
test determined significance (#p > 0.05; *p < 0.05; n = 30 or greater). Shown is a representative experiment 
performed in triplicate.
www.nature.com/scientificreports/
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assess tumor burden in transplanted mice, IgG2B serum levels were determined (Fig. 5C). Interestingly we could 
not detect decreases in IgG2B levels with the combination at 4 weeks, which may reflect decreased fitness for cells 
that survive the combination treatment. We had previously reported that selection for resistance to MTI-101 
resulted in a compromised CAM-DR phenotype and decreased adhesion to fibronectin and stroma cells15.
Sensitivity to MTI-101 is augmented in Relapsed vs. Primary Multiple Myeloma. To test the 
sensitivity of primary vs. relapsed myeloma specimens to MTI-101, CD138-positive malignant plasma cell frac-
tions from thirteen newly diagnosed and twelve relapsed primary MM specimens were treated with MTI-101. 
Consistent with our previous studies using the HYD1 linear analog of MTI-10115, MTI-101 was significantly 
more potent (p < 0.05, Student’s t-test) in relapsed than newly diagnosed MM specimens (Fig. 6A).
As 2-APB pretreatment inhibits MTI-101-induced death of MM cell lines, we tested whether this Ca2+ blocker 
would also impair MTI-101-induced cell death of primary MM specimens. Indeed, patient samples pretreated 
with 50 µM 2-APB were also more resistant to MTI-101 treatment (Fig. 6B p < 0.05, Student’s t-test). Thus, similar 
to MM cell lines, primary MM cells treated with MTI-101 die, at least in part, due to Ca2+ overload. Finally, as 
shown in Fig. 6C, the synergy between MTI-101 and bortezomib was observed in 5 out of the 6 primary patients, 
with pt135 showing synergy at 30 but not 60 hrs. Together these data indicate that combining MTI-101 with 
bortezomib maybe a good strategy for the treatment of multiple myeloma.
Discussion
MM is a disease that initially responds to chemotherapy. However, despite the range of mechanistically distinct 
therapies, the disease will eventually relapse and become refractory to further treatment, underscoring the need 
for novel treatment strategies. MM has high basal levels of ER stress due to the load of IgG production and is thus 
prone to initiate an unfolded protein response34. This increased ER load appears to contribute to the sensitivity 
of MM towards treatment with proteasome inhibitors. Our data support the notion that MM cells also rewire 
their Ca2+ circuitry, and that targeting Ca2+ signaling is an attractive therapeutic strategy for drug-resistant MM. 
Indeed, this may be a general feature of cancer cells, as demonstrated by increased expression of SOC and STIM1 
in multiple tumor types3, 4 and the required roles for elevated Ca2+ pools in cancer cell migration, invasion and 
metastasis5, 7. Our findings suggest that remodeling the Ca2+ circuitry occurs at a cost to fitness, rendering cells 
vulnerable to death induced by Ca2+ overload.
Our findings indicate that the acquisition of resistance to HYD1 and MTI-101 is associated with remodeling 
the circuitry that controls Ca2+ homeostasis. Specifically, drug resistance correlated with the suppression of IP3R, 
PLC, TRPC1, and TRPM7 expression and increased expression of TRPM6 and TRPM8 (Table 1). This switch 
in expression might reflect a compensatory response allowing for similar basal levels of Ca2+ to support growth 
in the face of MTI-101 treatment. Moreover, in this study, we showed that MTI-101 treatment as a single agent 
Figure 3. Blocking Ca2+ store operated calcium channels or inhibiting Ca2+ entry into mitochondria impairs 
MTI-101 induced cell death. (A) NCI-H929 and (B) U266 MM cells were pretreated with 50 μM-APB and 
5 μM Ru360 for 30 min or vehicle control (VC). After 30 min cells were treated with 10 or 20 μM of MTI-101, 
respectively, for 2 hr. MTI-101 specific cell death was measured by FACS analysis. Shown is a representative 
experiment performed in triplicate. (C) NCI-H929 and (D) U266 MM cells were pretreated with 50 µM of 
2-APB followed by treatment with 10 or 20 µM of MTI-101, respectively. Ca2+ levels were measured by fluo4 
AM. The Y-axis is depicted as gray scale units (GSU or pixel intensity).
www.nature.com/scientificreports/
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induces increased intracellular Ca2+ levels; a finding that contributes to MTI-101 induced cell death in MM cells. 
Evidence to support the role of Ca2+ release from the ER included data showing that the PLC inhibitor partially 
blocks MTI-101 induced Ca2+ levels. In addition, we showed that the SOC channel and IP3 receptor inhibitor 
2-APB attenuates MTI-101 mediated cell death in MM cell lines as well as primary patient derived CD138 plasma 
cells. Finally, we showed that MTI-101 induces STIM1 punctae near the plasma membrane, an event required for 
activation of store operated channels. Selection for resistance towards MTI-101 correlated with reduced expres-
sion of TRPC1 a component of the store operated channel. This finding guided our focus on the role of TRPC1. 
Indeed, we showed that a reduction TRPC1 partially inhibits MTI-101 induced MM cell death. Together, our 
results suggest that MTI-101 mediated increase in Ca2 is caused by release of Ca2+ from ER stores and Ca2+ entry 
via store-operated channel and that TRPC1 expression is a determinant of response in MM.
Treatment of cancer is typically most effective when combination strategies are implemented. Thus, it is 
important to place novel treatment strategies in context with standard of care agents. In this study, we showed 
that treatment with MTI-101 in combination with the standard of care agent Bortezomib demonstrates increased 
anti-myeloma activity in vitro and in vivo. Importantly, the synergy was maintained using CD138 cells derived 
from patients and cultured in an organotypic model which contained bone marrow stroma cell and collagen. 
These data indicate that MTI-101 in combination with the proteasome inhibitors is a tractable strategy for the 
development of this class of inhibitors. Mechanism of action of bortezomib includes inhibition of NF-κB activity 
and the induction of the unfolded protein response (UPR)34, 35. Accordingly, alterations in NF-κB pathways, the 
UPR and the induction of autophagy have been implicated in mediating resistance to bortezomib36, 37. Further, 
acquired resistance to bortezomib in cell line cultures has been linked to the identification of missense mutations 
(Ala49Thr) in the β5-subunit (PSMB5) of the proteasome and to increased expression of PSMB538, 39. However, 
sequencing efforts have failed to identify mutations in PSMB5 in clinical resistance to bortezomib40. Several 
Figure 4. MTI-101 activates STIM1 and reducing the expression of TRPC1 inhibits MTI-101 induced cell 
death. (A) U226 cells over expressing Stim1 m-cherry show increased trafficking to the plasma membrane 
following treatment with MTI-101 compared to control cells. Using TIRF microscopy, images of individual 
cells (n = 7) at each time point were visualized, analyzed, and linked through time. TIRF images were collected 
every 15 seconds over 30 minutes with the experimental group receiving a single 2.5 μM treatment of MTI-101 
at 30 seconds. Ft/F0 is the pixel intensity at the indicated time as denoted on the X axis divided by the average 
pixel density prior to drug treatment. Mean intensity data for STIM1 mCherry at each time point were extracted 
for comparisons. A representative cell from the control group and treatment group is shown before treatment 
(0 min) and after treatment (5 and 10 min). Shown is the mean and standard error of 7 cells for a representative 
experiment (p < 0.05, Two Way ANOVA). The experiment was repeated 3 independent times and similar data 
was obtained. (B and C). TRPC1 expression was reduced by using retroviral TRPC1 shRNA construct and 
expression was determined by Western Blot in U266 and MM1.S cells respectively. (B and C See Supplemntal 
Data S1). MM1.S and U266 cells were treated with different concentrations (5, 10 and 20 μM) of MTI-101 for 
48 hr and cell death was measured using PI staining. Cells with reduced TRPC1 levels cells showed a significant 
reduction in MTI-101 induced cell death (p < 0.05, Student’s t-test).
www.nature.com/scientificreports/
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reports indicated that blocking L-type Ca2+ channels or blocking Ca2+ uptake by inhibiting the mitochondria 
uniporter blocks cell death induced by bortezomib30, 31. It is attractive to speculate that synergistic cell death 
between MTI-101 and Bortezomib is driven via Ca2+ overload of the mitochondria in myeloma cells. However, 
recent studies indicate that inhibition of the proteasome can lead to necroptosis in a RIPK3 dependent pathway41. 
Thus, it is also feasible that the observed synergy between MTI-101 and bortezomib is due to augmentation of 
activation of RIPK3 leading to increased phosphorylation of MLKL and necroptosis. We currently favor the 
hypothesis that that as primary samples become resistant to bortezomib, myeloma cells may rewire Ca2+ homeo-
stasis to favor the induction of Ca2+ flux via store-operated channels rather than L-type channels, which underlies 
increased sensitivity to MTI-101 induced cell death in specimens obtained from patients relapsing on therapy. 
More studies are required to fully understand the mechanistic underpinning of synergy when MTI-101 is com-
bined with bortezomib and the increased activity of MTI-101 in relapsed patient specimens. In summary, MTI-
101 remains an attractive novel class of compounds to test as a front line combination strategy with proteasome 
inhibitors or in the setting of proteasome inhibitor refractory disease.
Materials and Methods
Cells and Reagents. NCI-H929 and U266 multiple myeloma (MM) cells were obtained from American 
Type Culture Collection (Manassas, VA) and maintained in RPMI-1640 medium supplemented with 10% FBS 
and 1% penicillin/streptomycin/glutamine. NCI-H929 cells were also supplemented with 0.05 mM beta-mer-
captoethanol. The HYD1 drug-resistant NCI-H929 cell line H929-60 was developed as previously described15. 
The parental and drug resistant line was validated by short tandem repeat (STR) analysis. 5TGM1 myeloma cells 
were derived from murine myeloma 5T33 and kept in similar media as U266 cells. All cell lines were tested for 
mycoplasma every six months. HYD1 (kikmviswkg) and MTI-101 were synthesized by Bachem (San Diego, CA). 
Bortezomib was purchased from Selleck Chem. The compounds U73122 (Sigma), 2-APB (Sigma) and Ru360 
(Merck Millipore) were all used to inhibit Ca2+ signaling.
Figure 5. Combination treatment with MTI-101 and bortezomib augments survival in vitro and in vivo.  
(A) 5TGM1 cells were treated with varying concentrations of MTI-101, bortezomib or the combination of both 
drugs for 72 hours using a bone marrow stroma model as described in materials and methods. Combination 
indexes (CI) for duplicate wells were calculated at 30 and 72 hrs. (B) 1 × 106 5TGM1 MM cells were injected into 
6–8 week old C57BL/KaLwRijHsd mice via tail vein. At day 10, mice were treated with 10 mg/kg of MTI-101 
and/or 0.5 mg/kg bortezomib three times a week for three weeks (10 mice per group). Mice were monitored 
daily for survival. Mean survival times for vehicle control, bortezomib only (p < 0.02, log-rank sum), MTI-
101 only (p < 0.01, log rank sum), and MTI-101/bortezomib (p < 0.001, log rank sum) combination therapy 
were 36, 42, 45.5, and 72.5 days, respectively. (C) IgG2B serum levels were measured by ELISA once a week for 
4 weeks to determine myeloma levels in the peripheral blood. At day 28 all drug treatment groups showed a 
significant decrease in IgG2B levels compared to control animals (p < 0.05).
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Gene Expression Profiling. Gene expression profiling was performed as previously described42. Briefly, 
100 ng of total RNA was isolated using a RNeasy mini kit (Qiagen). The oligonucleotide probe arrays used were 
the Human Genome U133 plus 2.0 Arrays. Data were processed and normalized using IRON. The mean expres-
sion values of the three experiments were compared between NCI-H929 and H929-60 MM and fold change were 
compared between mean expression in the two groups.
Real-Time PCR Analysis. 1 μg total RNA was used as a template to synthesize cDNA with the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA; Cat. no. 4368814) with a reaction volume 
of 50 μL. Real-time PCR was performed on the ABI 7900HT Fast Real-Time PCR System (Applied Biosystems) 
using assays specific for each gene of interest. Each reaction well contained 5μL of Power SYBR Green PCR Master 
Mix (cDNA equivalent to 20 ng of total RNA and 400 nM each of forward and reverse amplification primers in 
a reaction volume of 10 μL. Cycling conditions were as follows: 95 °C for 10 minutes for polymerase activation, 
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Data analysis was performed using Sequence 
Detection System software from Applied Biosystems, version 2.4. The experimental Ct (cycle threshold) was 
calibrated against the endogenous control product GAPDH. Real Time RTPCR was performed by ARQ genetics 
LLC Bastrop, TX. The following primer sets were used for amplification.
ATP2A3 For ward pr imer CCGGAACCACATGCACGAAG; Reverse  pr imer GGGGATG 
GCCATTCTGACCTC
Figure 6. Relapsed myelomas are more sensitive to MTI-101. Specimens were separated into two groups 
depending on clinical diagnosis; either newly diagnosed or relapsed patients. (A) CD138+ cells were treated 
with 10 µM of MTI-101 for 24 hr. After 24 hr cell death was measured by Annexin V staining and FACS analysis. 
CD138 cells derived from patients which have relapsed on therapy were significantly more sensitive to MTI-
101 induced cell death compared to CD138 cells obtained from newly diagnosed patients (p < 0.05, Student’s 
t-test) (B) CD138+ cells were pretreated with 50 µM 2APB or VC (vehicle control) for 30 min and then were 
treated with 10 µM MTI-101 for 24 hrs followed by FACS analysis. (C) Dose response surfaces for primary MM 
cells from patients treated ex vivo with bortezomib (50–0.6 nM, 3 fold serial dilution), MTI-101 (20–0.25 uM, 3 
fold serial dilultions)) and combination. Exposure time was 96 hrs except for patient pt129 (60 hrs). The actual 
combination of MTI-101 and bortezomib (MTI-101 + BTZ) is more effective (higher kill) than theoretical 
additive effect (ADDITIVE) indicating synergy between two drugs. Combination indexes (CI) were calculated 
using CalcuSyn software at 30 and 60 hrs. Samples were performed in duplicate and independent combination 
indexes were calculated for each patient specimen.
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PLCB1 (span Exon 4–5) Forward primer; GTGTCCGACAGCCTCAAGAA; Reverse primer ATCCCTGAGG 
GTCAGTCCTC
TRPC1 Forward primer CGGTTGTCAGAAACTAATGGAACG; Reverse primer CCTGAATTCCAC 
CTCCACAAGA
TRPM7 Forward primer CTGCTTTTGATCTCCTGTCCTGT; Reverse primer CAGACAGCC 
CATATTGCCCT
ITPR3 Forward primer GTTCCTGACGTGTGACGAGT Reverse primer GCCACCAGGCAGTACTTGAT
HGAPDH-forward primer TGCCCTCAACGACCACTTTG; reverse primer CTCTTCCTCTTGT 
GCTCTTGCTG
TIRF imaging of STIM1 mCherry. Imaging of STIM1 mCherry overexpressing U266 cells was performed 
using a total internal reflection fluorescence (TIRF) imaging system with objective lens 60x/1.49 Apo TIRF DIC in 
oil immersion using a Nikon Eclipse TE2000-E microscope (Melville, NY). Data were collected with a CoolSNAP 
HQ monochrome CCD camera (Tucson, AZ) and analyzed by NIS-Elements Software (Nikon Instruments, 
Melville, NY). mCherry-tagged STIM1 was excited with a 561-nm TIRF laser respectively, and emissions were 
collected using a 300-ms exposure time. TIRF images were collected every 15 seconds over 30 minutes with the 
experimental group receiving a single 2.5 μM treatment of MTI-101 at 30 seconds. Images of individual cells 
(n = 8) at each time point were analyzed and linked through time. Mean intensity data for STIM1 mCherry at 
each time point were extracted for comparisons. All experiments were carried out at 37 °C and 5% CO2.
shRNA knockdown of TRPC1 protein. pVSV-G envelope vector was transfected into gag-pol packaging 
genes containing GP-293 cells (63150, Clontech Laboratories, Inc, CA) with TRPC1 shRNA construct, plasmids 
containing these sequences (TG308629c, Origene Technologies, MD) to produce infectious ecotropic retrovi-
rus. The viral supernatants were collected 48 hours after transfection and used to infect cells in the presence of 
4 μg/mL Polybrene (Sigma-Aldrich, St Louis, MO). Briefly, MM1.S and U266 cells were infected with TRPC1, 
Scrambled virus for 24 hr and then removed the virus and incubated the cells with fresh medium for 72 hours 
before selecting cells with Puromycin. TRPC1 expression was determined by Western blot with the TRPC1 anti-
body (c-133076, Santa Cruz Biotechnology, CA).
Measurement of Intracellular Ca2+Concentrations. Intracellular free Ca2+ was measured using 
the Ca2+-sensitive dyes fura-2 and fluo-4 (Life Technologies). Glass-bottom microwell dishes (35 mm; Mattek 
Cultureware, Ashland, MA) were plated with 10-μL Cell-tak (BD Biosciences) per manufacturer’s instructions. 
Fura-2 and fluo-4 loading was performed by incubating the plated cells for 30 min at room temperature in 
either physiological saline solution (PSS). PSS is consist of 140 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 1.2 mM 
MgCl2, 7.7 mM glucose, and 10 mM HEPES (pH 7.2 with NaOH) or in PSS that did not contain CaCl2. For fura-
2, measurement of intracellular Ca2+ levels was performed as described43. Changes in intracellular Ca2+ levels 
were calculated using the grynkiewicz equation: [Ca2+] = KdQ(R − Rmin)/(Rmax − R). Calibration of the system 
was performed using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR), and values were 
determined to be as follows: Q = 23.04; Rmin = 0.31; Rmax = 8.87.
Ca2+ levels were also analyzed by confocal microscopy using fluo-4. Samples of NCI-H929 and U266 cells 
were observed with a Leica TCS SP5 AOBS laser scanning confocal microscope through a 63x/1.4NA Plan 
Apochromat oil-immersion objective lens (Leica Microsystems CMS GmbH, Germany). Argon 488 laser lines 
were applied to excite samples, and tunable emissions were used to minimize crosstalk between fluorochromes. 
Time-lapse (10-sec intervals for 22.5 min) images for each sample were captured with photomultiplier detectors 
and prepared with LAS AF software version 2.6 (Leica Microsystems). Maximum projection images of individual 
cells at each time point were analyzed using the Definiens® Developer v2.0 (Definiens AG, Munich, Germany) 
software suite. Fluo-4-stained cells were segmented by a combination of intensity and size thresholds. Segmented 
cells were linked through time, and mean intensity data for Fluo-4 at each time point were extracted from the 
segmentation.
Cell Death Analysis. After treatment with MTI-101, cells were washed with PBS and incubated with 2 nM 
TO-PRO-3 iodide (Life Technologies) or FITC Annexin V (BD biosciences) for 45 min. The cells were analyzed 
for fluorescence with the use of a FACSCalibur (BD Biosciences, San Jose, CA).
Measurement of cell death by PI staining. U266 and MM1.S (1 × 106 cells/1 ml) cells were incubated 
with different concentrations of MTI- 101(5, 10 and 20 µM) for 48 hours. Cells were washed 1x in PBS with 1% 
FBS, resuspended in 500 µl of buffer containing (5 µg/ml of PI) and incubated for 15 min at room temperature in 
the dark. Samples were analyzed with a BD FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) 
within 1 h. For each sample, 10 000 events were counted.
Primary Myeloma Patient Specimens. Patient specimens were from myeloma patients who provided 
written informed consent through the Moffitt Total Cancer Care® (MCC# 18608) tissue banking protocol per 
institutional and IRB regulations. Samples were provided to the laboratory as a de-identified sample from the 
Moffitt Tissue Core. Mononuclear cells were separated from human bone marrow aspirates with the use of 
Ficoll-Paque PLUS (GE Healthcare, UK). After separation, CD138-positive cells were sorted using MS MACS 
Separation Columns (Miltenyi Biotec, Germany) and CD138 microbeads (Miltenyi) per manufacturer’s instruc-
tions. For flow cytometry assays using Annexin V and FACS analysis to detect dead cells, CD138 cells were seeded 
at 1 million cells/ml in a 96 well plate (100 ul volume) per patient sample. The cell plating density was consistent 
across all specimens tested.
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Stromal cells. Primary MM cells were co-cultured with bone marrow derived stromal cells obtained from 
patients’ BM aspirates, as previously described44. Since this process takes weeks, primary MM cells from fresh 
biopsies were co-cultured with established stroma from prior patient samples.
Ex vivo assay. The ex vivo assay used to quantify chemo sensitivity of primary MM cells was described in 
detail previously45. Briefly, MM cells (CD138+) were seeded in multi-well plates with previously established 
human-derived stroma and collagen-I to a total volume of 8 µL containing approximately 4,000 MM cells and 
1,000 stromal cells. Drugs were added using a robotic plate handler, so that every drug was tested at five concen-
trations (1:3 serial dilution) and two replicates. Negative controls (supplemented growth media with and without 
vehicle control, DMSO) were included, as well as positive controls for each drug (cell line MM1.S at highest drug 
concentration). Plates were placed in a motorized stage microscope (EVOS Auto FL, Life Technologies) equipped 
with an incubator and maintained at 5% CO2 and 37 °C. Each well was imaged every 30 minutes for a total dura-
tion of four days.
Digital image analysis algorithm. We have developed a digital image analysis algorithm previously 
described45, 46 to determine changes in viability of each well longitudinally across the 96 h interval.
Drug combination and synergy analysis. To study interactions between MTI-101 and bortezomib in 
patient samples, we have added two drugs diluted serially, so that their concentration ratio remained the same 
across all wells tested. Thus the concentrations tested were (BTZ/MTI-101): 50 nM/20 µM, 16.7 nM/6.67 µM, 
5.6 nM/2.22 µM, 1.9 nM/0.74 µM and 0.6 nM/0.25 µM. To determine if there is synergy between the two drugs, 
we have plotted the dose-response surface of each drug individually, their actual combination, and the theoretical 
additive curve (Fig. 6). Here we use the classic definition of synergy, which determines that two drugs are syner-
gistic if their combined effect (percent cells killed) is higher than the combination of their independent effects47. 
For instance, consider that drugs A and B, at a specific concentration and during a certain period of time, kill the 
fractions a and b of cells, where a < 1 and b < 1. Should the combination of both drugs kill a fraction equal to 
[1 − (1 − a) * (1 − b)], then A and B are additive. If the fraction killed is higher, the drugs are synergistic; if lower, 
they are antagonistic.
Murine 5TGM1 Myeloma Model. Animal studies were conducted using 6- to 8-week-old female C57BL/
KaLwRijHsd mice (Harlan) in accordance with the NIH Guide for the Care and Use of Laboratory Animals and 
protocols were approved by the University of South Florida IACUC committee. 5TGM1 MM cells were injected 
i.v. via tail vein. Establishment of MM tumors in inoculated mice was followed by assaying immunoglobulin G2b 
(IgG2b) monoclonal paraprotein in sera prepared from whole blood obtained by a submandibular bleed. Mouse 
IgG2b levels were assayed by an ELISA (Bethyl Laboratories, Montgomery, TX) on days 7, 14, 21, and 28 per man-
ufacturer’s instructions. On day 10 after inoculation, mice began treatment with 10 mg/kg MTI-101 or 0.5 mg/kg 
bortezomib 3 times/week (Monday, Wednesday, Friday) for 21 days, for nine treatments. All drugs were adminis-
tered by IP injections. Mice were then examined until euthanization, which occurred when mice displayed hind 
leg paralysis or tumors grew in excess of 2 cm in diameter. On day 100, all remaining mice were euthanized.
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